Clinical Trials in Dallas

Showing 12981-13000 of 17,468 trials

COMPLETED< 1 mile

Clubfoot DNA Repository

NCT00607191

To build a DNA repository to enable participation in ongoing and future Clubfoot genetic linkage studies.

Clubfoot

Texas Scottish Rite Hospital for Children379 participantsStarted Jan 2008

Dallas, Texas, United States

COMPLETEDPhase 1< 1 mile

Dose-Escalation Study of GSK2126458

NCT00972686

P3K112826 is a Phase I, first-time-in-human dose escalation study in subjects with refractory malignancy. The primary objective of this study is to determine the recommended Phase II dose of GSK2126458 based on safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary evidence of clinical activity. Secondary objectives are to characterize the pharmacokinetics of GSK2126458; and to explore relationships between GSK2126458 pharmacokinetics, pharmacodynamics, response prediction biomarkers and clinical endpoints.

Solid Tumours

GlaxoSmithKline79 participantsStarted Aug 2009

San Francisco, California, United States • New Brunswick, New Jersey, United States • Chapel Hill, North Carolina, United States +6 more locations

COMPLETEDPhase 3< 1 mile

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160

Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 30. Secondary Objective: To compare the overall efficacy and safety of insulin glargine/lixisenatide FRC to insulin glargine (with or without metformin) over a 30 week treatment period in participants with type 2 diabetes.

Type 2 Diabetes

Sanofi736 participantsStarted Jan 2014

Birmingham, Alabama, United States • Sun City, Arizona, United States • Tempe, Arizona, United States +233 more locations

Clubfoot DNA Repository

Dose-Escalation Study of GSK2126458

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Find Trials by Condition in Dallas

Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer

Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics

Pulsed Radiofrequency Energy to Treat Post-Bunionectomy Pain

Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects